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Abstract The aim of our study was to develop a mod-
eling framework suitable to quantify the incidence,
absolute number and economic impact of osteoporosis-
attributable hip, vertebral and distal forearm fractures,
with a particular focus on change over time, and with
application to the situation in Switzerland from 2000 to
2020. A Markov process model was developed and
analyzed by Monte Carlo simulation. A demographic
scenario provided by the Swiss Federal Statistical Oﬃce
and various Swiss and international data sources were
used as model inputs. Demographic and epidemiologic
input parameters were reproduced correctly, conﬁrming
the internal validity of the model. The proportion of the
Swiss population aged 50 years or over will rise from
33.3% in 2000 to 41.3% in 2020. At the total population
level, osteoporosis-attributable incidence will rise from
1.16 to 1.54 per 1,000 person-years in the case of hip
fracture, from 3.28 to 4.18 per 1,000 person-years in the
case of radiographic vertebral fracture, and from 0.59 to
0.70 per 1,000 person-years in the case of distal forearm
fracture. Osteoporosis-attributable hip fracture numbers
will rise from 8,375 to 11,353, vertebral fracture numbers
will rise from 23,584 to 30,883, and distal forearm
fracture numbers will rise from 4,209 to 5,186. Popula-
tion-level osteoporosis-related direct medical inpatient
costs per year will rise from 713.4 million Swiss francs
(CHF) to CHF946.2 million. These ﬁgures correspond
to 1.6% and 2.2% of Swiss health care expenditures in
2000. The modeling framework described can be applied
to a wide variety of settings. It can be used to assess the
impact of new prevention, diagnostic and treatment
strategies. In Switzerland incidences of osteoporotic hip,
vertebral and distal forearm fracture will rise by 33%,
27%, and 19%, respectively, between 2000 and 2020, if
current prevention and treatment patterns are main-
tained. Corresponding absolute fracture numbers will
rise by 36%, 31%, and 23%. Related direct medical
inpatient costs are predicted to increase by 33%; how-
ever, this estimate is subject to uncertainty due to limited
availability of input data.
Keywords Economics Æ Epidemiology Æ Europe Æ
Modeling studies Æ Osteoporosis Æ Switzerland
Introduction
Osteoporosis is an important health problem in elderly
women and, to a lesser extent, in elderly men [1]. Oste-
oporotic fragility fractures occur at multiple sites of the
skeletal system [2], but the main focus of research is on
fractures of the hip, vertebrae and distal forearm [1].
These fracture types occur frequently and show a steep
rise in incidence with age, more pronounced in women
than in men [1, 3]. Most serious consequences are ob-
served in hip and vertebral fracture patients. The impact
of hip fracture is dramatic in terms of morbidity, mor-
tality, loss of functional independence, and cost [1, 4].
Worldwide projections have predicted a doubling of
hip fracture cases from 1990 to 2025, with the ageing of
the populations being one of the most important causes
[5, 6]. The expected rise will be particularly pronounced
in Asia, but Western societies will be aﬀected, too [5, 7].
Despite an awareness of these general trends,
detailed simulations of the future impact of osteoporosis
are rare. Several Markov-based modeling studies have
assessed lifetime fracture risk and long-term fracture
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consequences [8, 9, 10, 11], but only one, focusing on the
situation in Florida, has examined the expected health
burden of osteoporosis in the ﬁrst quarter of the 21st
century [12].
In Switzerland, countrywide data on the occurrence
and impact of osteoporotic fractures are sparse, with the
last comprehensive assessment describing the situation
in 1992 [13]. Forecasts of future fracture incidences and
impact were based on these data and did not apply up-
to-date modeling techniques [14, 15]. A Swiss Markov
model, addressing the socioeconomic impact of hip
fracture, has been published as a short report only [16].
A clear lack of planning data has been recognized by the
health authorities.
Given this situation, we aimed at developing a Mar-
kov-based modeling framework using Monte Carlo
simulation, suitable to quantify the incidence, absolute
number and economic impact of osteoporotic hip, ver-
tebral and distal forearm fractures, currently and in the
future. Intended features were applicability to a wide
variety of countries and situations, and the ability to
assess the impact of future changes in disease incidence,
osteoporosis-related medical practice, and cost. The ﬁrst
application was to the Swiss population in 2000, 2010
and 2020. The methodological objective of this appli-
cation was to test the model in a well-deﬁned and stable
Western population with a high share of elderly people.
At the same time the existing knowledge gap with re-
spect to the current situation and the developments to be
expected in Switzerland was to be ﬁlled.
Materials and methods
Model characteristics
Using DATA Professional (Tree Age, Williamstown,
Mass., USA), we developed a four-stage Markov pro-
cess model comprising the following mutually exclusive
health states: alive without fracture; alive with at least
one distal forearm or vertebral fracture, but no hip
fracture; alive with at least one hip fracture; dead. Other
fracture sites were not taken into account. We used
Monte Carlo simulation to run a large number of indi-
viduals through the model separately, allowing for a
subject-by-subject random assignment of characteristics.
We used tracker variables to record individual event
histories, taking into account non-osteoporotic and
osteoporotic fractures, acute hospital care, inpatient
rehabilitation episodes, nursing home admissions, and
cost. Thus, the ‘‘memory-less’’ feature of Markov cohort
models was overcome [17].
We modeled all event entries using a cycle length of 1
month, in order to reduce any distortions related to the
time distribution of events occurring. An individual
could sustain one fracture per cycle. Rates were con-
verted into cumulative probabilities to allow for correct
Markov state transitions between cycles [18]. Where
appropriate, a half-cycle correction was implemented.
For the application to Switzerland, two diﬀerent
kinds of simulation were used. First, a cohort repre-
senting the Swiss population of a certain year aged 50
years or older was observed for 1 year. Based on a
random assignment of gender and age, 500,000 simu-
lated persons were run through the model. Total and
osteoporosis-related hip, vertebral, and distal forearm
fractures were counted. We observed fracture-related
resource use and costs for another 6 months, without
allowing for additional fracture entries, in order to
achieve a mean follow-up time of 1 year after fracture
entry. Second, a cohort representing all Swiss persons
aged 50 years in a certain year was observed for the
remainder of their lives. Based on a random assignment
of gender, 12,500 simulated persons were run through
the model. Costs were calculated undiscounted and
discounted by 3% per year. Inﬂation or changes in
inpatient care cost due to changing medical practice
were not modeled. Owing to the extended observation
period per subject, the relative importance of long-term
nursing home costs was adequately taken into account.
On this basis, estimates of mean yearly inpatient costs
due to recent, as well as earlier, fractures could be cal-
culated.
Model inputs
Published or publicly available Swiss data sources were
used wherever possible. Otherwise, European data and,
if necessary, data from the USA and Australia were
used. Plausibility of all model inputs was assessed by
comparison with published literature.
Demographic data: The Swiss Federal Statistical Of-
ﬁce (SFSO) has issued a series of demographic scenarios
projecting the development of the Swiss population be-
tween 2000 and 2060 [19]. Age and gender distributions
used in the main analysis are those described by the
SFSO main scenario, which extrapolates current demo-
graphic trends and thus avoids extreme assumptions. In
this scenario, the proportion of the population aged 50
years or over will rise from 33.3% in 2000 to 41.3% in
2020. The share of those aged 65 or over will rise from
15.4% to 20.0%. Figure 1 compares the age distribu-
tions expected for 2000 and 2020.
Fracture incidences: Swiss hospitals are obliged to
report patient-level inpatient data to the SFSO. Gender-
and age-speciﬁc hip fracture incidences were estimated
from the ICD-10 S72.0–S72.2 cases reported to the
SFSO in 2000, with the assumption of a hip fracture
hospitalization rate of 100%. Reporting was incomplete,
and the SFSO calculated a relation of reported to ex-
pected cases of 0.811. This ﬁgure was used with the
assumption of a random distribution of non-reporting.
Swiss-based gender- and age-speciﬁc data on vertebral
and distal forearm fracture incidence were not available.
Cases reported to the SFSO could not be used here, as
valid Swiss data on hospitalization probabilities do not
exist. Published data show that hip fracture rates are
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similar in Switzerland and in Western Europe [6, 20]. It
was assumed that the same relationship exists for other
types of osteoporotic fractures, and morphometric ver-
tebral fracture incidences for Western Europe reported
by the EPOS group were used [21]. Missing data points
after age 79 years were estimated by linear extrapolation
[21, 22, 23, 24]. In the case of distal forearm fracture, the
incidences reported by Kanis et al. for Malmo¨, Sweden,
provided suﬃcient detail [23]. These were multiplied by a
correction factor of 0.55, derived from the EVOS data,
as distal forearm fracture incidences are higher in
Northern Europe than in Western Europe [1, 25]. Inci-
dences above age 89 years were assumed to be identical
to those in the age group 85–89 years [22, 23, 24]. The
incidence rates used are summarized in Table 1.
Osteoporosis-attributable fractures: The share of
osteoporosis-attributable fractures, i.e., of fractures that
would not have occurred if no osteoporotic changes had
been present in the skeletal system, by fracture type,
gender and age was modeled by way of a stochastic
process that used the attribution probabilities described
by Melton et al. for the white population in the USA
[26]. Calculation of osteoporosis-attributable fracture
incidences and numbers at the total population level
assumed no osteoporosis-related fractures under the age
of 50 years.
Mortality: All-causemortality by year, gender and age
was taken from the SFSO main demographic scenario
[19]. Short- and long-term excess mortality after hip
fracture was modeled from data collected by Trombetti
Fig. 1 Age distribution of the
Swiss population, 2000 and
2020 compared, according to
the Swiss Federal Statistical
Oﬃce’s main demographic
scenario
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et al. in canton Geneva, Switzerland [27]. Those authors
observed an unadjusted in-hospital mortality rate of 8%
in women and 15% in men. The combination of their
original data and the Swiss age distribution starting at age
50 years led to an age-adjusted excess mortality rate of 53
per 1,000 person-years in women and 206 per 1,000 per-
son-years in men, in the ﬁrst year after fracture. In the
second to ﬁfth years, excess mortality rates per year were
103 per 1,000 person-years in women and 127 per 1,000
person-years in men. Long-term excess mortality after
vertebral fracture was modeled on relative risks of 1.6 in
women and 1.2 in men, as found in the EPOS study after
multivariate adjustment [28, 29, 30]. For both types of
fracture, excessmortalitywas limited to a periodof 5 years
after fracture entry [10, 27, 29, 31, 32]. Excess mortality
after distal forearm fracture and short-term excess mor-
tality after vertebral fracture were not modeled [1]. To
avoid an overestimation of total mortality, all-cause
mortality was reduced by the approximate population-
level impact of fracture-associated mortality.
The probability that a vertebral fracture would come
to clinical attention and be treated was estimated to be
30% [33, 34, 35]. The probability of an acute hospital-
ization episode was assumed to be 33% after a vertebral
fracture had come to clinical attention [1, 35]. In the case
of distal forearm fracture, a hospitalization probability
of 53.0% was estimated from the incidence data used
and the inpatient cases with ICD-10 codes S52.5–6 re-
ported to the SFSO in 2000. This estimate takes into
account all patients that occupy a hospital bed, even be
it for a few hours only.
Year 2000 acute care lengths of stay were calculated
from the SFSO data. In the case of vertebral fracture,
ICD-10 codes M48.5, M80.0–9, M84.0, M84.4 and T08
were taken into account. Participation in an inpatient
rehabilitation program after hip fracture was assumed to
occur in 68% of women and 36% of men, with a length
of stay of 59 and 54 days, respectively [27]. Rehabilita-
tion programs after vertebral or distal forearm fracture
were not taken into account.
Swiss year 2000 census data were used to estimate
gender- and age-speciﬁc probabilities of being cared for
in a nursing home, and of being admitted to such an
institution, for any reason. The overall share of fracture-
induced nursing home admissions was assumed to be
8%, following a German source [36]. Based on data
from canton Geneva, Switzerland, the overall proba-
bility of long-term nursing home admission after hip
fracture in those living in an apartment before the
fracture event was assumed to be 18% [27, 37]. Gender-
and age-speciﬁc admission probabilities were estimated
under the assumption of a linear increase with age.
Residency in a nursing home for any reason and the
event of being admitted to a nursing home due to hip
fracture were modeled in parallel. Residency in a nursing
home was counted as fracture-induced until a nursing
home admission for any reason would have occurred.
Nursing home admissions due to vertebral or distal
forearm fractures were not taken into account.
Adopting a societal perspective, we assessed direct
medical costs of acute inpatient hospital care, inpatient
rehabilitation and nursing home residency by multiply-
ing length of stay with the estimated daily real costs by
type of institution as reported by the SFSO for the year
2000. The results were veriﬁed against Swiss and inter-
national data sources [38, 39, 40, 41]. All costs are
indicated in year 2000 Swiss francs (CHF). On 31 Dec
2000, CHF1 equaled 0.66 euros.
Analysis of model output
Using STATA/SE (version 8.0, Stata Corporation,
College Station, Tex., USA) and standard statistical
procedures, we analyzed the output data. Calculation of
95% conﬁdence intervals (95% CIs) was based on bias-
corrected bootstrapping using 1,000 repetitions. Due to
limitations of available computation time, calculation of
CIs was restricted to key output parameters.
Internal and external model validation
Correct reproduction of main input parameters was
examined to test the internal validity of the model.
Comparisons included the gender and age distributions
and life expectancies of the underlying demographic
scenario, as well as gender- and age-speciﬁc incidence
rates. External plausibility of results was assessed by
comparison with published data as detailed in the Dis-
cussion.
Sensitivity analysis
While Monte Carlo simulation was used to deal with
ﬁrst-order uncertainty (individual variation in gender
and age), the impact of second-order parameter uncer-
tainty was assessed by classic deterministic sensitivity
Table 1 Gender- and age-speciﬁc fracture incidence rates, per 1,000
person-years, as used in the main analysis
Age (years) Hip fracture Vertebral
fracturea
Distal forearm
fracture
Female Male Female Male Female Male
50–54 0.31 0.49 3.6 0.9 2.3 0.6
55–59 0.68 0.79 5.5 5.5 2.5 0.8
60–64 1.09 0.91 9.5 4.8 3.1 0.8
65–69 2.15 1.59 12.3 6.3 3.8 1.6
70–74 4.14 2.29 17.9 8.7 5.0 0.5
75–79 8.51 4.49 29.3 13.6 5.7 1.0
80–84 17.71 7.46 34.4b 16.1b 6.7 1.4
85–89 32.31 14.84 39.6b 18.7b 7.7 1.8
90–94 41.43 24.96 44.7b 21.2b 7.7c 1.8c
95+ 44.04 46.28 49.9b 23.8b 7.7c 1.8c
aRadiographic fractures
bExtrapolated from the available datapoints
cAssumed to remain constant after age 85–89 years
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analysis. Ranges of variation are shown in Table 2. In
order to limit calculation time, we combined several
parameter changes that prompted fewer fracture events
and lower costs, and tested them simultaneously in a
best-case scenario. Parameter changes that prompted
more fracture events and higher costs were tested in a
worst-case scenario. Varied parameters comprised: gen-
der- and age-speciﬁc incidences; osteoporosis attribution
probabilities; treatment, hospitalization and rehabilita-
tion probabilities; the probability of a new admission to
a nursing home after hip fracture; lengths of stay; acute
care, rehabilitation and nursing home costs per day. In a
separate analysis, approximate outpatient hip fracture
costs of CHF6,442 per case were added [42]. Back-
ground nursing home residency and disease-speciﬁc
mortality were also varied separately. Additional anal-
yses modeled disease-speciﬁc mortality as age-speciﬁc or
replaced the SFSO main demographic scenario with
alternative scenarios that described either a less or a
more pronounced ageing of the population [19]. Finally,
we repeated the main analysis but included a secular 1%
per year rise of gender- and age-speciﬁc hip fracture
incidence rates [1, 6].
Results
Internal validation
The gender and age distributions of the underlying
demographic scenario were reproduced correctly. The
proportion of women in the population aged 50 years or
older was 54.6% (95% CI 54.4–54.7) in 2000, 53.8%
(95% CI 53.7–53.9) in 2010 and 53.5% (95% CI 53.3–
53.6) in 2020. Mean age ± SD of those aged 50 years or
older rose from 65.0±11.0 (95% CI 64.9–65.0) years in
2000 and 65.2±10.9 (95% CI 65.2–65.2) years in 2010 to
65.6±10.8 (95% CI 65.6–65.6) years in 2020. Predicted
life expectancy at age 50 years was 31.8±10.4 (95% CI
31.7–32.0) years in 2000, 32.8±10.1 (95% CI 32.6–32.9)
years in 2010 and 33.4±9.6 (95% CI 33.3–33.6) years in
2020. These results compare well with the SFSO esti-
mates of 32.0 years in 2000, 32.8 years in 2010 and 33.4
years in 2020. Gender- and age-speciﬁc fracture inci-
dences used on the input side were also reproduced
correctly. First hip fractures were estimated to occur at
an age of 79.8 years, on average, in 2000. This compares
well with a broad estimate of 80.5 years as directly de-
rived from the SFSO data. In the latter case, no dis-
tinction between ﬁrst and repeated fractures could be
made.
Fractures
Tables 3 and 4 summarize total and osteoporosis-
attributable fracture incidences and absolute fracture
numbers by gender. For all parameters a rise is seen
between 2000 and 2020, with the exception of the inci- T
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dence of distal forearm fractures in women aged 50
years and over, which is constant at the all-fracture level
and slightly decreases when only osteoporosis-attribut-
able fractures are taken into account. Related absolute
minima will occur in 2010.
For all ages combined, osteoporosis-attributable hip
fracture incidence will rise from 1.16 to 1.54 per 1,000
person-years (+32.8%), osteoporosis-attributable ver-
tebral fracture incidence from 3.28 to 4.18 per 1,000
person-years (+27.4%), and osteoporosis-attributable
distal forearm fracture incidence from 0.59 to 0.70 per
1,000 person-years (+18.6%). Osteoporosis-attribut-
able fracture numbers at the total population level will
rise from 8,375 to 11,353 (+35.6%) in the case of hip
fracture, from 23,584 to 30,883 (+30.9%) in the case of
vertebral fracture, and from 4,209 to 5,186 (+23.2%) in
the case of distal forearm fracture.
Lifetime fracture risk
For all combinations of fracture type and gender, life-
time risk at age 50 years will rise between 2000 and 2020.
Lifetime hip fracture risk will rise from 14.7% to 16.4%
(women: 20.9% to 23.1%, men: 8.7% to 9.7%). Lifetime
vertebral fracture risk will rise from 30.7% to 33.8%
(women: 42.6% to 46.1%, men: 19.1% to 21.7%), and
distal forearm fracture risk from 8.1% to 8.9% (women:
13.8% to 14.9%, men: 2.7% to 3.1%). Osteoporosis-
attributable lifetime risk will rise from 13.0% to 14.4%
(women: 19.2% to 21.2%, men: 7.0% to 7.6%) in the
case of hip fracture, from 27.8% to 30.7% (women:
39.0% to 42.5%, men: 17.0% to 19.0%) in the case of
vertebral fracture, and from 5.6% to 6.1% (women:
10.1% to 10.9%, men: 1.2% to 1.5%) in the case of
distal forearm fracture.
Resource use
Table 5 shows the number of acute hospitalizations and
the days spent in acute care hospitals, inpatient reha-
bilitation facilities, and nursing homes, due to fractures,
in 1000 persons aged 50 years and over, in 2000, 2010
and 2020. Results for the Swiss population from age 50
on are added. Days of stay occurring until 1 year after
fracture entry are taken into account. For all parame-
ters, a rise is seen between 2000 and 2020. However,
estimates per 1,000 persons show a non-monotonic
development in some cases, with their maxima or min-
ima in 2010. Population-level increases are more pro-
nounced due to the growth of population size.
Costs
Figure 2 shows direct medical inpatient costs arising in
the Swiss population from age 50 on, induced by frac-
tures in 2000, 2010 and 2020, during the ﬁrst year after T
a
b
le
5
N
u
m
b
er
s
o
f
d
a
y
s
sp
en
t
in
d
iﬀ
er
en
t
ty
p
es
o
f
in
st
it
u
ti
o
n
s,
u
n
ti
l
1
y
ea
r
a
ft
er
fr
a
ct
u
re
en
tr
y
,
d
u
e
to
h
ip
,
v
er
te
b
ra
l
a
n
d
d
is
ta
l
fo
re
a
rm
fr
a
ct
u
re
s
o
cc
u
rr
in
g
in
th
e
y
ea
r
o
f
re
fe
re
n
ce
P
a
ra
m
et
er
A
ll
fr
a
ct
u
re
s
O
st
eo
p
o
ro
si
s-
re
la
te
d
fr
a
ct
u
re
s
Y
ea
r
2
0
0
0
2
0
1
0
2
0
2
0
In
cr
ea
se
2
0
0
0
2
0
1
0
2
0
2
0
In
cr
ea
se
2
0
0
0
–
2
0
2
0
2
0
0
0
–
2
0
2
0
P
er
1
,0
0
0
p
er
so
n
s
fr
o
m
a
g
e
5
0
y
ea
rs
a
N
u
m
b
er
o
f
a
cu
te
h
o
sp
it
a
li
za
ti
o
n
s
6
.4
0
6
.4
7
6
.5
5
+
2
.3
%
5
.3
3
5
.4
1
5
.5
0
+
3
.2
%
(6
.1
8
–
6
.6
2
)
(6
.2
5
–
6
.6
9
)
(6
.3
3
–
6
.7
8
)
(5
.1
3
–
5
.5
4
)
(5
.2
1
–
5
.6
2
)
(5
.3
0
–
5
.7
1
)
D
a
y
s
in
a
cu
te
ca
re
h
o
sp
it
a
ls
9
5
.6
9
7
.5
9
9
.2
+
3
.4
%
8
2
.7
8
4
.5
8
6
.3
+
4
.4
%
(9
2
.6
–
9
9
.3
)
(9
4
.1
–
1
0
1
.0
)
(9
5
.8
–
1
0
2
.6
)
(7
9
.6
–
8
6
.3
)
(8
1
.6
–
8
8
.1
)
(8
3
.0
–
8
9
.5
)
D
a
y
s
in
in
p
a
ti
en
t
re
h
a
b
il
it
a
ti
o
n
fa
ci
li
ti
es
1
3
9
.0
1
4
2
.5
1
4
1
.7
+
1
.9
%
1
2
3
.2
1
2
8
.2
1
2
7
.7
+
3
.7
%
(1
3
1
.3
–
1
4
7
.5
)
(1
3
4
.6
–
1
5
0
.1
)
(1
3
3
.6
–
1
4
9
.4
)
(1
1
6
.1
–
1
3
1
.0
)
(1
2
0
.6
–
1
3
5
.2
)
(1
2
0
.4
–
1
3
5
.2
)
D
a
y
s
in
n
u
rs
in
g
h
o
m
es
1
4
9
.9
1
4
6
.5
1
5
6
.5
1
3
2
.8
1
3
3
.2
1
4
4
.3
(1
2
9
.4
–
1
7
0
.3
)
(1
2
8
.5
–
1
6
5
.0
)
(1
3
6
.7
–
1
7
8
.2
)
+
4
.4
%
(1
1
3
.9
–
1
5
1
.9
)
(1
1
6
.2
–
1
5
2
.4
)
(1
2
5
.4
–
1
6
6
.0
)
+
8
.7
%
S
w
is
s
p
o
p
u
la
ti
o
n
fr
o
m
a
g
e
5
0
y
ea
rs
N
u
m
b
er
o
f
a
cu
te
h
o
sp
it
a
li
za
ti
o
n
s
1
5
,3
2
0
1
7
,5
5
9
1
9
,9
7
7
+
3
0
.4
%
1
2
,7
6
3
1
4
,6
9
7
1
6
,7
8
0
+
3
1
.5
%
D
a
y
s
in
a
cu
te
ca
re
h
o
sp
it
a
ls
2
2
9
,0
1
3
2
6
4
,8
4
2
3
0
2
,5
4
5
+
3
2
.1
%
1
9
7
,9
8
7
2
3
0
,1
3
0
2
6
3
,3
1
4
+
3
3
.0
%
D
a
y
s
in
in
p
a
ti
en
t
re
h
a
b
il
it
a
ti
o
n
fa
ci
li
ti
es
3
3
2
,8
4
2
3
8
7
,0
5
9
4
3
2
,1
8
5
+
2
9
.8
%
2
9
5
,0
6
6
3
4
8
,1
4
4
3
8
9
,6
3
1
+
3
2
.0
%
D
a
y
s
in
n
u
rs
in
g
h
o
m
es
3
5
8
,8
9
0
3
9
5
,4
1
4
4
7
7
,4
0
3
+
3
3
.0
%
3
1
7
,8
8
0
3
6
1
,8
3
3
4
4
0
,0
9
4
+
3
8
.4
%
a
N
u
m
b
er
s
in
p
a
re
n
th
es
es
a
re
9
5
%
co
n
ﬁ
d
en
ce
in
te
rv
a
ls
665
fracture. Costs of all fractures and of those attributable
to osteoporosis are presented in parallel.
Total ﬁrst-year inpatient costs will rise by 31.5% at
the all-fracture level, from CHF443.7 million (CI 422.8–
462.9 million) to CHF583.5 million (CI 559.2–
609.7 million). Point estimates correspond to 1.0% and
1.3% of Swiss health care expenditure in 2000. At the
osteoporosis-attributable fracture level there will be a
rise by 33.5%, from CHF388.2 million (CI 369.1–
406.4 million) to CHF518.3 million (CI 494.9–
544.7 million). Point estimates correspond to 0.9% and
1.2% of Swiss health care expenditure in 2000.
The relative shares of acute care hospital, inpatient
rehabilitation and nursing home costs in the ﬁrst year
after osteoporosis-related fracture will remain fairly
constant over time. In 2000, acute hospital care con-
tributes 51.5% (2020: 51.3%), inpatient rehabilitation
contributes 33.4% (2020: 33.1%), and nursing home
care 15.1% (2020: 15.7%). Results at the all-fracture
level are similar.
The relative importance of nursing home costs is
much higher if undiscounted lifetime inpatient costs
from age 50 years on are considered. Long-term cost
consequences of fractures are included in this perspec-
tive, which results in a proportion of nursing home costs
that is near constant over time at 53.3%–54.3%.
These percentages broadly reﬂect the contribution of
nursing home costs to yearly fracture- and osteoporotic
fracture-induced inpatient costs taking into account the
consequences of earlier fractures. If an average value of
53.8% is adopted, yearly fracture-related inpatient costs
can be estimated at CHF817.2 million in 2000 and at
CHF1,072.4 million in 2020 (+31.2%), which corre-
spond to 1.9% and 2.5% of Swiss health care expendi-
ture in 2000. Osteoporosis-attributable costs can be
estimated at CHF713.4 million in 2000 and at
CHF946.2 million in 2020 (+32.6%), which correspond
to 1.6% and 2.2% of Swiss health care expenditure in
2000.
Lifetime fracture-related inpatient costs from age 50
on, per 1,000 persons observed, will rise from
CHF13.7 million in 2000 (CI 12.3–15.4 million; dis-
counted by 3%: CHF5.4 million) to CHF15.2 million in
2020 (CI 13.8–16.6 million; discounted: CHF5.7 mil-
lion). If only osteoporosis-attributable fractures are re-
garded, the rise will be from CHF11.9 million in 2000
(CI 10.6–13.3 million; discounted: CHF4.6 million) to
CHF13.5 million in 2020 (CI 12.3–15.0 million; dis-
counted: CHF5.0 million).
Sensitivity analysis
The eﬀects of input parameter variation on key outcome
parameters are shown in Table 6.
Implementation of the best and worst case scenarios
described in the Methods strongly impacted on all epi-
demiologic and economic outcome parameters. For
example, the incidence of year 2000 osteoporosis-
attributable hip fractures, for all ages combined, was
changed by ±31.9%. Population level, osteoporosis-
attributable, ﬁrst-year inpatient costs were reduced by
57.7% in the best case and increased by 93.7% in the
worst case. If estimated outpatient hip fracture costs of
CHF6,552 per case were taken into account, this led to
an absolute increase of osteoporosis-attributable costs
Fig. 2 Inpatient costs of fractures of the hip, vertebrae and
forearm, until 1 year after fracture entry, occurring in the Swiss
population from age 50 years
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by 13.8%. In contrast, if we varied the proportion of the
population that were living in a nursing home, varied the
level of disease-speciﬁc mortality, or modeled disease-
speciﬁc mortality as age-speciﬁc, it hardly aﬀected the
absolute results. Relative parameter changes between
2000 and 2020 were only marginally aﬀected by all
modiﬁcations named so far. When the SFSO main
demographic scenario was replaced by alternative sce-
narios that described a less-pronounced or a more-pro-
nounced ageing of the population, relative increases in
the incidence of osteoporosis-attributable fractures be-
tween 2000 and 2020 were slightly less pronounced in the
former case and more pronounced in the latter (in the
case of hip fracture, +26.7% and +41.2% compared to
+32.8% in the main analysis). However, there was no
impact on the resource use and cost results. When a 1%
per year secular rise in the incidences of gender- and age-
speciﬁc hip fractures was modeled, relative changes be-
tween 2000 and 2020 were inﬂated by a factor of 2 to 4
when compared with the main analysis. The incidence of
osteoporosis-attributable hip fractures increased by
+61.2%, and population level, osteoporosis-attribut-
able, ﬁrst-year inpatient costs by +57.5%.
Discussion
The modeling framework described here allows one to
assess the epidemiologic and economic consequences of
osteoporotic hip, vertebral and distal forearm fractures.
There is a particular focus on change over time, e.g.,
related to demographic developments. If suitable input
data are available, the model can be applied to a wide
variety of countries and settings. While the application
to Switzerland, presented here as a test case, was purely
descriptive, the epidemiological and economic impact of
new preventive or treatment strategies, or of any chan-
ges occurring in medical practice, can easily be modeled
as soon as related eﬀect estimates are available.
To our knowledge this is the second study, interna-
tionally, that used a Markov process model, and the ﬁrst
one that used the Monte Carlo technique, to simulate
the development of osteoporotic fracture incidences and
numbers, associated resource use, and cost over an ex-
tended period of time [12]. While future fracture occur-
rence alone could be estimated by simpler means, the
synthesis of data from various sources and the assess-
ment of several interlinked output parameters are most
consistently achieved by the use oﬀ the Markov ap-
proach. More importantly, long-term observation of
simulated individual disease histories, e.g., allowing for
the estimation of lifetime fracture risk, requires such a
methodology [12, 17]. The advantages of Monte Carlo
simulation in particular are highlighted by a comparison
with the methodological approach described in a re-
cently published work by Burge et al., who assessed the
epidemiology and economic impact of osteoporosis in
Florida for 2000–2025 [12]. Relying on a conventional
Markov cohort model, Burge et al. had to run a large
number of separate simulations, one for each combina-
tion of year of age and race. Simulation outputs were
combined, and the impact of demographic change was
assessed by way of separate procedures outside the
Markov module. By contrast, the Monte Carlo tech-
nique enabled us to forego additional modeling steps.
Additional calculations were limited to the statistics re-
quired to address the chance component inherent in all
Monte Carlo-based results.
While models are generally characterized by a
reduction in complexity compared to reality, some sim-
pliﬁcations in the present case were dictated by an
anticipated lack of appropriate input data. For example,
we relied on a set of Markov states that solely described
fracture event history, in contrast to some osteoporosis
models that incorporated functional status or type of
residence at the disease state level [8, 10, 16]. Owing to a
lack of detailed fracture incidence data that distin-
guished between persons without and with osteoporosis,
modeling of fracture entries was not based on the ab-
sence or presence of the underlying disease [10]. Diﬀer-
ent fracture incidences in persons without or with
previous fractures, or in persons living either in the
community or in nursing homes, were not taken into
account [10]. The model was built in such a way that the
simpliﬁcations described can be abandoned easily when
adequate input data become available. Technical cor-
rectness of the model was assessed by comparison of
output parameters with related input parameters, with
completely satisfactory results.
Besides developing and testing methodology, this
study aimed at closing a gap of information on the fu-
ture occurrence and consequences of osteoporosis-
attributable hip, vertebral, and distal forearm fractures
in Switzerland. According to our results, the incidence of
these fracture types at the Swiss population level will rise
by 19%–33% between 2000 and 2020. Corresponding
absolute fracture numbers will rise by 23%–36%. Re-
lated direct medical inpatient costs per year are pre-
dicted to increase by 33%.
The expected increase in the number of osteoporosis-
related hip fractures, from 8,375 in 2000 to 11,353 in
2020, conﬁrms the magnitude of earlier estimates [1, 6,
7]. For Switzerland in 2020, Meine et al. [15] expected
15,000 hip fractures and Lippuner and Jaeger [14] ex-
pected 14,436, for all ages combined and without
excluding non-osteoporotic fractures. Calculated life-
time risks are well in the range to be expected from the
literature. For example, our result of a 21% lifetime hip
fracture risk in women aged 50 years in 2000 compares
well with published estimates from various industrialized
countries, indicating a risk of 14%–23% at this age [4, 8,
10, 20, 23]. In men aged 50 years, our result of 9%
compares with published estimates of from 6%–11%
[23, 35, 43].
Constant or slightly decreasing incidence rates of
distal forearm fractures, as observed in women aged 50
years and over, and non-monotonic developments over
time in some resource use parameters, are explained by
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shifts in the age structure above age 50 as modeled by
the SFSO main scenario. Residual inﬂuences of chance
may have played an additional role.
For the fracture types taken into account here,
Lippuner et al. reported 290,972 osteoporosis-
attributable days spent in acute care hospitals in 1992
and related costs of CHF245.9 million [13]. Our cor-
responding results of 197,987 hospital days and costs of
CHF199.8 million in 2000 are distinctly lower. While
the diﬀerent registration methods and coding systems
used might have contributed to this eﬀect, the main
reason lies in reduced lengths of stay. In particular,
mean acute care length of stay after hip fracture fell
dramatically, from 29.1 days in 1992 to 17.7 days in
2000 [13]. It can be assumed that this decrease was
enabled by improved medical practice but also
encouraged by budgetary constraints in the Swiss
health care system. It may have been accompanied by a
still unmeasured increase in the use of outpatient
medical and nursing services and, consequently, in
outpatient costs. Missing information on outpatient
costs hindered a realistic assessment of total direct
medical costs.
The ﬁnding that long-term nursing home costs con-
tributed 54% of total inpatient costs is consistent with
ﬁndings from 1998 onwards, which indicated that long-
term care costs are responsible for 40%–75% of osteo-
porosis-related inpatient costs in the USA [12].
Sensitivity analyses demonstrated stable relative
parameter changes between 2000 and 2020 except for
when a 1% per year secular rise of fracture incidence
was modeled. In fact, there is no strong evidence for an
ongoing secular rise in Europe or in the USA [1, 6].
Absolute results, however, showed considerable varia-
tion, which highlighted that relevant uncertainty was
present in some of the input parameters available. These
were of diﬀerent quality and, in part, of non-Swiss ori-
gin. For example, for vertebral and distal forearm
fractures, European incidence data had to be used and,
in the latter case, adjusted for geographic diﬀerences.
This was justiﬁed by various literature sources, but, still,
the inputs derived may, to a certain extent, deviate from
Swiss reality [22, 25, 35, 44].
The osteoporosis attribution probabilities applied,
reported by Melton et al., were estimated by an expert
panel that used a Delphi process, and they compare well
with earlier estimates published by Phillips et al. [26, 45].
Attribution probabilities have been used by several au-
thors to model osteoporosis-related fracture occurrence
[12, 13].
Modeling of hip fracture mortality was based on
Swiss short-term and long-term data reported by
Trombetti et al. [27], which are in line with various Swiss
and international data sources [31, 37, 46]. In particular,
1-year cumulative mortality was near identical in the
study by Trombetti et al. (women: 19%, men: 39%), in
an earlier Swiss study by Schu¨rch et al. (women: 21%,
men: 35%) [37], and in the Australian study by Center
et al. (women: 20%; men: 37%) [31].
The estimate of a 53% hospitalization probability
after distal forearm fracture in the population aged 50
years or older reﬂects Swiss hospitalization data and,
thus, ensures consistency in our economic results. Pa-
tients that occupy a hospital bed for only a few hours
were taken into account here, which may explain, in
part, why this value is in accordance with a Swiss source
that indicated a hospitalization probability of 70% at
age 85 years, but not with two international sources that
hinted at a probability of approximately 10% only from
age 40 onwards [9, 35, 47]. The latter value was used as a
lower boundary in sensitivity analysis.
This study focused on the occurrence and impact of
osteoporosis-attributable hip, vertebral, and distal
forearm fractures. An assessment of total osteoporosis-
related fracture occurrence, resource use and cost would
have to take into account additional fracture sites, such
as the humerus, ribs and pelvis, but it was not under-
taken for reasons of data availability. Another slight
tendency for the model to underestimate the impact of
osteoporosis may have been introduced by our not
considering osteoporotic fracture occurrence under the
age of 50 years. Due to a lack of data, inpatient reha-
bilitation episodes caused by vertebral and distal fore-
arm fractures could not be taken into account, which
may have impacted on costs estimates.
In summary, in Switzerland the incidences of oste-
oporotic hip, vertebral and distal forearm fractures will
rise, respectively, by 33%, 27%, and 19%, between
2000 and 2020, if current prevention and treatment
patterns are maintained. Corresponding absolute frac-
ture numbers per year will rise by 36%, 31%, and
23%. The increase in hip fractures will be most pro-
nounced. Main causes are (1) a shift toward higher
ages within the population from age 50 years on, (2) a
relative growth of the population from age 50 on
within the total population, and (3) absolute popula-
tion growth. Main assumptions are that demographic
reality will essentially conﬁrm the SFSO main scenario
and that age- and gender speciﬁc incidence rates will
remain constant. Related direct medical inpatient costs
per year are predicted to increase by 33%
(CHF232.8 million), but this result is aﬀected by
uncertainty due to a lack of knowledge of future
developments of treatment patterns, economic circum-
stances, and resource unit prices. Moreover, currently,
total direct medical costs cannot be estimated due to
missing data on outpatient costs. When additional
information becomes available, this modeling frame-
work can be used for a re-assessment.
In more general terms, this modeling framework,
which focuses on hip, vertebral, and distal forearm
fractures, can be applied to a wide variety of situations
in order to forecast future developments and assess the
impact of changing medical practice and changing
economic circumstances. The incorporation of addi-
tional fracture sites is also feasible. Limitations will
usually be due to the limited availability of adequate
input data.
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